Trial
NCT03005184
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Vanderbilt University Medical Center
Collaborators
—
Condition
Heart Failure NYHA Class I
Intervention
Valsartan 80 mg bid
Why stopped
Study is being redesigned and submitted as a new study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-11